doi: 10.1038/nrd2572.
The nociceptin/orphanin FQ receptor: a _target with broad therapeutic potential
Affiliations
- PMID: 18670432
- DOI: 10.1038/nrd2572
Item in Clipboard
The nociceptin/orphanin FQ receptor: a _target with broad therapeutic potential
Nat Rev Drug Discov.
2008 Aug.
Abstract
Identification of the enigmatic nociceptin/orphanin FQ peptide (N/OFQ) in 1995 represented the first successful use of reverse pharmacology and led to deorphanization of the N/OFQ receptor (NOP). Subsequently, the N/OFQ-NOP system has been implicated in a wide range of biological functions, including pain, drug abuse, cardiovascular control and immunity. Although this could be considered a hurdle for the development of pharmaceuticals selective for a specific disease indication, NOP represents a viable drug _target. This article describes potential clinical indications and highlights the current status of the very limited number of clinical trials.
Similar articles
-
The biology of Nociceptin/Orphanin FQ (N/OFQ) related to obesity, stress, anxiety, mood, and drug dependence.Pharmacol Ther. 2014 Mar;141(3):283-99. doi: 10.1016/j.pharmthera.2013.10.011. Epub 2013 Nov 1. Pharmacol Ther. 2014. PMID: 24189487 Free PMC article. Review.
-
Nociceptin/orphanin FQ peptide receptor antagonist JTC-801 reverses pain and anxiety symptoms in a rat model of post-traumatic stress disorder.Br J Pharmacol. 2015 Jan;172(2):571-82. doi: 10.1111/bph.12701. Epub 2014 Jul 1. Br J Pharmacol. 2015. PMID: 24666365 Free PMC article.
-
Nociceptin/orphanin FQ peptide receptors: pharmacology and clinical implications.Curr Drug _targets. 2007 Jan;8(1):117-35. doi: 10.2174/138945007779315605. Curr Drug _targets. 2007. PMID: 17266536 Review.
-
Spotlight on Nociceptin/Orphanin FQ Receptor in the Treatment of Pain.Molecules. 2022 Jan 18;27(3):595. doi: 10.3390/molecules27030595. Molecules. 2022. PMID: 35163856 Free PMC article. Review.
-
Nociceptin/orphanin FQ and its receptor--potential _targets for pain therapy?J Pharmacol Exp Ther. 2003 Aug;306(2):423-9. doi: 10.1124/jpet.102.046979. Epub 2003 Apr 29. J Pharmacol Exp Ther. 2003. PMID: 12721334
Cited by
-
Supraspinal actions of nociceptin/orphanin FQ, morphine and substance P in regulating pain and itch in non-human primates.Br J Pharmacol. 2015 Jul;172(13):3302-12. doi: 10.1111/bph.13124. Epub 2015 Apr 24. Br J Pharmacol. 2015. PMID: 25752320 Free PMC article.
-
Functional Selectivity Does Not Predict Antinociceptive/Locomotor Impairing Potencies of NOP Receptor Agonists.Front Neurosci. 2021 Mar 30;15:657153. doi: 10.3389/fnins.2021.657153. eCollection 2021. Front Neurosci. 2021. PMID: 33859548 Free PMC article.
-
Acute and chronic antiparkinsonian effects of the novel nociceptin/orphanin FQ receptor antagonist NiK-21273 in comparison with SB-612111.Br J Pharmacol. 2013 Feb;168(4):863-79. doi: 10.1111/j.1476-5381.2012.02219.x. Br J Pharmacol. 2013. PMID: 22994368 Free PMC article.
-
Synthesis, Biological Activity and Molecular Docking of Chimeric Peptides _targeting Opioid and NOP Receptors.Int J Mol Sci. 2022 Oct 21;23(20):12700. doi: 10.3390/ijms232012700. Int J Mol Sci. 2022. PMID: 36293553 Free PMC article.
-
Binding of GTPgamma[35S] is regulated by GDP and receptor activation. Studies with the nociceptin/orphanin FQ receptor.Br J Pharmacol. 2010 Mar;159(6):1286-93. doi: 10.1111/j.1476-5381.2009.00621.x. Epub 2010 Feb 10. Br J Pharmacol. 2010. PMID: 20148892 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
